AlphaMark Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $278K | Buy |
10,468
+8,565
| +450% | +$232K | 0.12% | 107 |
|
|
2024
Q3 | $55K | Buy |
1,903
+200
| +12% | +$5.83K | 0.02% | 329 |
|
|
2024
Q2 | $48K | Buy |
1,703
+650
| +62% | +$17.9K | 0.02% | 345 |
|
|
2024
Q1 | $29K | Sell |
1,053
-650
| -38% | -$18K | 0.01% | 404 |
|
|
2023
Q4 | $49K | Sell |
1,703
-20
| -1% | -$605 | 0.02% | 347 |
|
|
2023
Q3 | $57K | Sell |
1,723
-426
| -20% | -$15.1K | 0.02% | 312 |
|
|
2023
Q2 | $79K | Sell |
2,149
-170
| -7% | -$6.62K | 0.04% | 183 |
|
|
2023
Q1 | $95K | Buy |
2,319
+325
| +16% | +$14K | 0.04% | 168 |
|
|
2022
Q4 | $102K | Sell |
1,994
-297
| -13% | -$14.2K | 0.05% | 147 |
|
|
2022
Q3 | $100K | Sell |
2,291
-2,500
| -52% | -$121K | 0.05% | 151 |
|
|
2022
Q2 | $251K | Sell |
4,791
-15
| -0.3% | -$764 | 0.12% | 96 |
|
|
2022
Q1 | $249K | Sell |
4,806
-210
| -4% | -$10.9K | 0.09% | 110 |
|
|
2021
Q4 | $296K | Sell |
5,016
-202
| -4% | -$10K | 0.1% | 108 |
|
|
2021
Q3 | $224K | Buy |
5,218
+92
| +2% | +$4.08K | 0.08% | 119 |
|
|
2021
Q2 | $201K | Buy |
5,126
+1,100
| +27% | +$42.8K | 0.07% | 125 |
|
|
2021
Q1 | $146K | Sell |
4,026
-1,200
| -23% | -$42.6K | 0.06% | 150 |
|
|
2020
Q4 | $192K | Buy |
5,226
+1,615
| +45% | +$59.2K | 0.07% | 110 |
|
|
2020
Q3 | $126K | Buy |
3,611
+843
| +30% | +$29.6K | 0.05% | 132 |
|
|
2020
Q2 | $86K | Sell |
2,768
-15
| -0.5% | -$510 | 0.04% | 154 |
|
|
2020
Q1 | $86K | Buy |
2,783
+121
| +5% | +$4.12K | 0.05% | 136 |
|
|
2019
Q4 | $99K | Buy |
2,662
+368
| +16% | +$13.1K | 0.04% | 155 |
|
|
2019
Q3 | $78K | Sell |
2,294
-146
| -6% | -$5.31K | 0.03% | 173 |
|
|
2019
Q2 | $100K | Hold |
2,440
| – | – | 0.04% | 157 |
|
|
2019
Q1 | $98K | Buy |
2,440
+146
| +6% | +$5.85K | 0.04% | 150 |
|
|
2018
Q4 | $95K | Hold |
2,294
| – | – | 0.05% | 144 |
|
|
2018
Q3 | $96K | Sell |
2,294
-421
| -16% | -$16.2K | 0.04% | 179 |
|
|
2018
Q2 | $93K | Hold |
2,715
| – | – | 0.04% | 183 |
|
|
2018
Q1 | $91K | Sell |
2,715
-264
| -9% | -$9.08K | 0.04% | 173 |
|
|
2017
Q4 | $102K | Hold |
2,979
| – | – | 0.04% | 160 |
|
|
2017
Q3 | $101K | Hold |
2,979
| – | – | 0.04% | 151 |
|
|
2017
Q2 | $95K | Sell |
2,979
-421
| -12% | -$13.3K | 0.04% | 150 |
|
|
2017
Q1 | $110K | Buy |
3,400
+923
| +37% | +$29.1K | 0.05% | 135 |
|
|
2016
Q4 | $76K | Buy |
2,477
+158
| +7% | +$4.82K | 0.04% | 144 |
|
|
2016
Q3 | $75K | Hold |
2,319
| – | – | 0.04% | 122 |
|
|
2016
Q2 | $77K | Sell |
2,319
-105
| -4% | -$3.35K | 0.05% | 117 |
|
|
2016
Q1 | $68K | Hold |
2,424
| – | – | 0.04% | 119 |
|
|
2015
Q4 | $74K | Hold |
2,424
| – | – | 0.04% | 118 |
|
|
2015
Q3 | $72K | Sell |
2,424
-949
| -28% | -$30.4K | 0.04% | 111 |
|
|
2015
Q2 | $107K | Hold |
3,373
| – | – | 0.06% | 113 |
|
|
2015
Q1 | $111K | Sell |
3,373
-6,143
| -65% | -$195K | 0.06% | 112 |
|
|
2014
Q4 | $281K | Sell |
9,516
-3,372
| -26% | -$96.7K | 0.17% | 83 |
|
|
2014
Q3 | $362K | Buy |
12,888
+1,054
| +9% | +$29.6K | 0.23% | 77 |
|
|
2014
Q2 | $333K | Buy |
11,834
+1,370
| +13% | +$39.1K | 0.2% | 84 |
|
|
2014
Q1 | $319K | Sell |
10,464
-316
| -3% | -$9.42K | 0.2% | 82 |
|
|
2013
Q4 | $313K | Sell |
10,780
-685
| -6% | -$19.9K | 0.2% | 81 |
|
|
2013
Q3 | $312K | Hold |
11,465
| – | – | 0.2% | 82 |
|
|
2013
Q2 | $305K | Buy |
+11,465
| New | +$317K | 0.19% | 85 |
|
Other funds holding PFE
AlphaMark Advisors's PFE Position: Q4 2024 in Review
AlphaMark Advisors increased its Pfizer (PFE) stake by 450% in Q4 2024, buying an estimated $232K and bringing the position to 10,468 shares worth $278K. The position accounts for 0.12% of the portfolio, ranked #107.
AlphaMark Advisors first reported a position in PFE in Q2 2013 and has held it in 47 quarters since. The position peaked at $362K in Q3 2014. 2,996 funds tracked by Wall St. Rank hold PFE as of Q4 2024.
- AlphaMark Advisors held 10,468 shares of Pfizer worth $278K as of Q4 2024.
- AlphaMark Advisors bought 8,565 Pfizer shares in Q4 2024, an estimated $232K.
- Pfizer made up 0.12% of AlphaMark Advisors's portfolio in Q4 2024, its #107 holding.
- AlphaMark Advisors first reported a position in Pfizer in Q2 2013 and has held it in 47 quarters since.
- AlphaMark Advisors's Pfizer position peaked at $362K in Q3 2014.
- 2,996 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.
Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.